MedTrace Logo

Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis

NCT06236152 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-02-01

No results posted yet for this study

Summary

This study will be conducted as a single blinded randomized control trial. The goal of this clinical trial is to learn about the role of low dose steroids in the resolution of tuberculous lymphadenitis. The prime questions, this clinical trial aims to answer are:

* Is there any role of starting low dose steroids in resolution of lymph node size along side standard anti-tubercular drugs in patients of tuberculous lymphadenitis?
* Do low dose steroid therapy in addition to standard anti-TB drugs prevents or reduces the incidence of complications?

Patients presenting to the out patient department of Pak Emirates Military Hospital, Rawalpindi with tuberculous lymphadenitis will be recruited in the study after a written informed consent. Initial size of two largest lymph nodes will be measured. They will be randomized into two groups, only one of which will be receiving the low dose steroids.

The patients will be followed up on a monthly basis and regression in the lymph node size, if any will be measured. The two groups will be compared at the end of the trial.

Conditions

  • Tuberculous Lymphadenitis, Cervical

Interventions

DRUG

Ferrous sulfate

Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.

DRUG

Deltacortril

Deltacortil 10mg was given orally once daily for 4 to 6 weeks

Sponsors & Collaborators

  • Fahad Javed Awan

    lead OTHER

Principal Investigators

  • Fahad J Awan, MBBS · Pak Emirates Military Hospital

  • Muhammad Uneeb Ullah, MBBS · Pak Emirates Military Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-06-30
Completion
2023-08-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236152 on ClinicalTrials.gov